Reference : Combination therapy versus monotherapy: a randomised pilot study on the evolution of inf...
Scientific journals : Article
Human health sciences : Anesthesia & intensive care
http://hdl.handle.net/2268/73009
Combination therapy versus monotherapy: a randomised pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia
English
Damas, Pierre mailto [Université de Liège - ULg > > Soins intensifs >]
Garweg, Christophe mailto [Centre Hospitalier Universitaire de Liège - CHU > > Cardiologie >]
Monchi, Mehran [> >]
Nys, Monique mailto [Centre Hospitalier Universitaire de Liège - CHU > > Soins intensifs - Anesthésie et réanimation >]
Canivet, Jean-Luc mailto [Centre Hospitalier Universitaire de Liège - CHU > > Soins intensifs >]
Ledoux, Didier mailto [Centre Hospitalier Universitaire de Liège - CHU > > Soins intensifs >]
Preiser, Jean-Charles mailto [Centre Hospitalier Universitaire de Liège - CHU > > Soins intensifs >]
2006
Critical Care
BioMed Central
10
2
R52
Yes
International
1364-8535
1466-609X
London
United Kingdom
[en] Introduction Combination antibiotic therapy for ventilator
associated pneumonia (VAP) is often used to broaden the
spectrum of activity of empirical treatment. The relevance of
such synergy is commonly supposed but poorly supported. The
aim of the present study was to compare the clinical outcome
and the course of biological variables in patients treated for a
VAP, using a monotherapy with a beta-lactam versus a
combination therapy.
Methods Patients with VAP were prospectively randomised to
receive either cefepime alone or cefepime in association with
amikacin or levofloxacin. Clinical and inflammatory parameters
were measured on the day of inclusion and thereafter.
Results Seventy-four mechanically ventilated patients meeting
clinical criteria for VAP were enrolled in the study. VAP was
microbiologically confirmed in 59 patients (84%). Patients were
randomised to receive cefepime (C group, 20 patients),
cefepime with amikacin (C-A group, 19 patients) or cefepime
with levofloxacin (C-L group, 20 patients). No significant
difference was observed regarding the time course of
temperature, leukocytosis or C-reactive protein level. There
were no differences between length of stay in the intensive care
unit after infection, nor in ventilator free days within 28 days after
infection. No difference in mortality was observed.
Conclusion Antibiotic combination using a fourth generation
cephalosporin with either an aminoside or a fluoroquinolone is
not associated with a clinical or biological benefit when
compared to cephalosporin monotherapy against common
susceptible pathogens causing VAP.
Researchers ; Professionals
http://hdl.handle.net/2268/73009

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
88.pdfPublisher postprint214.62 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.